INFOGRAPHICS

Insight into CKD progression: Ophthalmalogical outcomes and eGFR in non-diabetic CKD

OPHTHALMOLOGY NEPHROLOGY
21 Jun 2024

Get access to our exclusive articles.
Related Articles

Expanding horizons from DKD to CKD: A cardio-kidney-metabolic approach

This lecture emphasizes the urgent need for early detection and intervention in CKD, noting that even mild cases require prompt action, including consideration of SGLT2 inhibitors like empagliflozin, which have demonstrated the potential to significantly delay kidney replacement therapy by over 26 years.

17 Sep 2025

HKU study defines serum lithium thresholds for the treatment of bipolar disorder linked to thyroid and renal risk complications

Bipolar disorder (BD) is a chronic condition associated with relapse and elevated suicide risk, for which lithium remains a key maintenance therapy to reduce recurrence, readmission, and self-harm. However, concerns about its renal and thyroid effects persist. 
PSYCHIATRY
02 Sep 2025

Thinking ahead: The need for early diagnosis and treatment in a broad spectrum of CKD

This lecture by Professor Christoph Wanner emphasizes the importance of early diagnosis and treatment of chronic kidney disease (CKD), particularly in patients with cardiovascular comorbidities, advocating for comprehensive screening methods and timely treatment to improve patient outcomes.

21 Oct 2024

Sotagliflozin prevents cardiovascular events regardless of the left ventricular ejection fraction and presence of albuminuria

Type 2 diabetes mellitus (T2DM) is known to be associated with a 33% greater risk of hospitalization for heart failure (HF) and an increase in the risk of cardiovascular and overall death.1 Patients with coexisting T2DM and chronic kidney disease (CKD) are at further risk of HF and ischemic events t
CARDIOLOGY
28 Feb 2021

Chronic kidney disease: Atrial fibrillation and the risk of other cardiovascular diseases

Atrial fibrillation, a distinct form of cardiovascular disease (CVD), is common in chronic kidney disease (CKD) patients.1 It increases the risk of CKD patients developing stroke.2 Intervention with warfarin is prevalent in patients with atrial fibrillation,

NEPHROLOGY
30 Aug 2019

Transforming treatment in the management of SHPT with etelcalcetide

Secondary hyperparathyroidism (SHPT) is a very common condition in patients with chronic kidney disease (CKD).1,2 Cinacalcet, a calcimimetic that is commonly used to treat patients with SHPT, has been recommended by well-recognized guidelines but appears to have some shortfalls with non-adherence issues.3,4
NEPHROLOGY
29 Nov 2018